



Bharat Parenterals Limited

Registered Office & Works:

Survey No.: 144-A, Jarod-Samlaya Road, Vill. Haripura,
Ta. Savli, Dist. Vadodara - 391520 (Guj.) India.

Mobile : 99099 28332

E-mail: info@bplindia.in, Web.: www.bplindia.in

CIN NO: L24231GJ1992PLC018237

(WHO-GMP CERTIFIED ★ STAR EXPORT HOUSE)

Date: 17th June, 2022

To,
BSE Limited,
P.J. Towers,
Dalal Street,
Mumbai - 400001

Ref.: Company Code: 541096

Dear Sir / Madam,

Sub: Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We bring to your kind attention that the Board of Directors of the company at their meeting held on 16th June, 2022 accorded their approval for the following matters:

1. We wish to inform you that pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and subject to the provisions of the SEBI (Share Based Employee Benefits) Regulations, 2014 (hereinafter referred to as SEBI Regulations), the Board of Directors of the company at its meeting held on 16th June, 2022 as per the recommendation of NRC, has granted 45,000 stock options to the employees of the Company, under the second trench of Employee Stock Option Plan 2020 (BPL-ESOP 2020) at an exercise price of Rs. 99 per stock option. Each of the stock option entitles the holder to apply for one equity share of the Company of Rs.10/- each and at a premium of Rs.89/- each.

The following are the terms of the options granted:

- a) Vesting Period: Vests over a period of 1 year.
 - b) Other Terms: The shares arising out of the exercise of stock options are proposed to be allotted. The ESOPs granted are governed as per BPL ESOP 2020 Scheme, which has already submitted with the exchanges at the time of obtaining the in-principle approval.
2. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform that the Board of Directors has proposed to incorporate a subsidiary with the desired name, "**VARENYAM BIOLIFESCIENCES PRIVATE LIMITED**" already confirmed by the Registrar, Central Registration Centre regarding availability of the said name for adoption vide name availability letter dated 13-06-2022, through SPICe+ and pursuant to Section



7 of the Companies Act, 2013 read with Rules made thereunder. The Company is in the process of incorporation and yet to be incorporated.

The details as required under Regulation 30 of the Listing Regulations read with SEBI circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is attached herewith as Annexure.

You are requested to take the same on record.

Thanking You,

FOR BHARAT PARENTERALS LIMITED



Lubhanshi Jhalani
Company Secretary



ANNEXURE

S. No.	Particulars	Description
1.	Name of the Target Proposed Company, details in brief such as size, turnover, etc.	<p>VARENYAM BIOLIFESCIENCES PRIVATE LIMITED will be incorporated as a subsidiary of the Company (name approved)</p> <p>Proposed Authorised Capital: Rs 10,00,00,000</p> <p>Size/Turnover : Not applicable (yet to be incorporated and commence business operations)</p>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	<p>Varenyam Biolifesciences Private Limited is promoted by Bharat Parenterals Limited (the 'Company').</p> <p>The promoter/promoter group /group companies are interested in the company.</p> <p>The company is yet to be incorporated and commence its business operations</p>
3.	Industry to which the entity being acquired belongs	Pharmaceutical
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	<p>The Subsidiary is incorporated to carry on the business of Manufacturing and trading of Pharmaceutical Formulations and products including Biotechnology products covered under the Biotechnology policy (2022-2027) of the Central or State Government of India.”</p> <p>The business of subsidiary is in line with the main object of business of the Company.</p>



5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
6.	Indicative time period for completion of the acquisition	Not applicable
7.	Nature of consideration - whether cash consideration or share swap and details of the same	60% subscription of share capital in Cash
8.	Cost of acquisition or the price at which the shares are acquired	The Company will subscribe to 60% of the paid up equity of the proposed company.
9.	Percentage of shareholding / control acquired and/ or number of shares acquired	60% (proposed to be acquired)
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Product Line- Manufacturing and trading of Pharmaceutical Formulations and products including Biotechnology products covered under the Biotechnology policy (2022-2027) of the Central or State Government of India.”</p> <p>Date of Incorporation: To be incorporated (Name approved)</p> <p>History/ Turnover - Not applicable</p> <p>Varenyam Biolifesciences Private Limited is yet to be incorporated in India and commence its business operations.</p>

